Literature DB >> 2314588

Pharmacokinetics and safety of a phenytoin prodrug given i.v. or i.m. in patients.

I E Leppik1, B A Boucher, B J Wilder, V S Murthy, C Watridge, N M Graves, R J Rangel, C A Rask, P Turlapaty.   

Abstract

ACC-9653, a prodrug of phenytoin synthesized to be water soluble, is converted to phenytoin by phosphatases. In this study, 43 patients received ACC-9653 IV or IM. Side effects were transient and minor. The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively. Peak phenytoin concentrations occurred 42 minutes after IV and 151 minutes after IM administration.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2314588     DOI： 10.1212/wnl.40.3_part_1.456

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.

Authors:  J C DeToledo; R E Ramsay
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

3.  Canine status epilepticus: a translational platform for human therapeutic trials.

Authors:  Ilo E Leppik; Edward N Patterson; Lisa D Coles; Elise M Craft; James C Cloyd
Journal:  Epilepsia       Date:  2011-10       Impact factor: 5.864

Review 4.  Fosphenytoin. Pharmacoeconomic implications of therapy.

Authors:  S M Holliday; P Benfield; G L Plosker
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

5.  Canine status epilepticus treated with fosphenytoin: A proof of principle study.

Authors:  Edward E Patterson; Ilo E Leppik; Lisa D Coles; Michael Podell; Charles H Vite; William Bush; James C Cloyd
Journal:  Epilepsia       Date:  2015-05-07       Impact factor: 5.864

Review 6.  The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.

Authors:  E Perucca; M Bialer
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

7.  Animal models for the development of new neuropharmacological therapeutics in the status epilepticus.

Authors:  Ed Martín; Ma Pozo
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

Review 8.  Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy.

Authors:  Sima I Patel; Angela K Birnbaum; James C Cloyd; Ilo E Leppik
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

Review 9.  Status epilepticus. Clinical features, pathophysiology, and treatment.

Authors:  C Watson
Journal:  West J Med       Date:  1991-12

10.  Pharmacokinetics of phenytoin following intravenous and intramuscular administration of fosphenytoin and phenytoin sodium in the rabbit.

Authors:  S N Muchohi; G O Kokwaro; T E Maitho; R W Munenge; W M Watkins; G Edwards
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Apr-Jun       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.